Tranexamic Acid Dosage for Topical Treatment of Anterior Epistaxis

• Status: Completed
• Trial end date: 2023-03-15
• Target enrollment: 0
• Participant gender: All

Summary

Patients with epistaxis usually apply to the emergency department for initial treatment. According to recent research, tranexamic acid is effective in the treatment of epistaxis. The research compare the therapeutic superiority of saline with 500 and 1000 mg doses of topical tranexamic acid in the treatment of anterior epistaxis. The design of the phase 4 clinical trial was randomized controlled double-blind. A total of 152 cases in 3 groups were included in the study. Group 1 was treated with 1000 mg of tranexamic acid, group 2 with 500 mg of tranexamic acid, and group 3 with saline. The primary outcome of the study was bleeding control at the 5th and 10th minutes. Secondary outcomes were determined as the need for salvage therapy, recurrent bleeding within 24 hours, the presence of side effects, and the need for otorhinolaryngology consultation.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Izmir Ataturk Training and Research Hospital
• Treatments: Tranexamic Acid

Criteria

Inclusion Criteria:

• 18 years and older

• Those who applied to the emergency department with the complaint of nosebleeds

• Those who agreed to participate in the study by giving written consent

Exclusion Criteria:

• posterior epistaxis

• history of nose or pharynx surgery in the last 3 months,

• facial and head trauma,

• unstable vital signs,

• who applied for the second time with a recurrent bleeding

• history of allergy to TXA,

• subarachnoid hemorrhage,

• coagulation disorders such as hemophilia, hereditary telangiectasia, von Willebrand disease, etc.

• thromboembolic disease

• history of convulsions

• intracerebral processes

• pregnant or lactating

• who wished to withdraw from the study at any stage of the study